Bookmark and Share

Douglas D. Ross M.D., Ph.D.

Academic Title: Professor
Primary Appointment: Medicine
Secondary Appointments: Pathology, Pharmacology
Additional Title(s): Director, Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center
Location: BRB Room 9-031
Phone: (410) 328-8095
Fax: (410) 328-6559
Lab: (410)-328-3685

Research Interests:

Dr. Ross’ research interests include molecular pharmacology relating to antineoplastic drug mechanisms of action and neoplastic cellular mechanisms of resistance to anticancer agents. The detection of drug resistance in blast cells from patients with acute leukemia has been a major focus of study. Mechanistic studies have investigated cytosine arabinoside, gemcitabine, daunorubicin, and idarubicin. Clinical studies of blast cells from acute leukemia patients by Dr. Ross revealed evidence of functional expression of a drug transporter-based resistance mechanism that was greater than could be accounted for by the measured expression of P-glycoprotein or the multidrug resistance protein in these cells. These studies led to a search for new multidrug resistance transporters, and eventually to the discovery to the novel multidrug resistance transporter Breast Cancer Resistance Protein (BCRP/ABCG2). In addition to laboratory research, Dr Ross is actively involved with education in palliative medicine, and has recently led a team that integrated approximately 20 hours of required classroom and experiential training in hospice and palliative care into the curriculum of the University of Maryland School of Medicine, supported by an R25 grant from the NCI.


Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006 Mar 16; [Epub ahead of print] PMID: 16543472 [PubMed - as supplied by publisher]

Ross DD, Shpritz D, Hull MM, Goloubeva O. Long-term evaluation of required coursework in palliative and end-of-life care for medical students. J Palliat Med. 2005 Oct;8(5):962-74. PMID: 16238509 [PubMed - indexed for MEDLINE]

Ee PL, He X, Ross DD, Beck WT.  Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther. 2004 Dec;3(12):1577-83. PMID: 15634651 [PubMed - indexed for MEDLINE]

Ross DD, Shpritz D, Alexander CS, Carter K, Edelman MJ, Friedley N, Hemani A, Keay TJ, Roy SC, Silverman H, Tasker DJ, Timmel D, Schwartz J, Wolfsthal SD.  Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellows. J Cancer Educ. 2004 Summer;19(2):81-7. PMID: 15456662 [PubMed - indexed for MEDLINE]

Ross DD, Doyle LA.  Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell. 2004 Aug;6(2):105-7. PMID: 15324691 [PubMed - indexed for MEDLINE]

Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD.  The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004 Jun 4;279(23):24218-25. Epub 2004 Mar 24. PMID: 15044468 [PubMed - indexed for MEDLINE]

Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT.  Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 2004 Feb 15;64(4):1247-51. PMID: 14973083 [PubMed - indexed for MEDLINE]

Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD.  Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol. 2003 Dec;64(6):1452-62. PMID: 14645676 [PubMed - indexed for MEDLINE]

Doyle LA, Ross DD.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003 Oct 20;22(47):7340-58. Review. PMID: 14576842 [PubMed - indexed for MEDLINE]

Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD.  Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res. 2003 Aug 15;9(9):3320-8. PMID: 12960118 [PubMed - indexed for MEDLINE]

Ross DD, Fraser HC, Kutner JS. Institutionalization of a palliative and end-of-life care educational program in a medical school curriculum. J Palliat Med. 2001 Winter;4(4):512-8. PMID: 11798486 [PubMed - indexed for MEDLINE]

Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD.  Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta. 2001 Sep 21;1520(3):234-41. PMID: 11566359 [PubMed - indexed for MEDLINE]

Ross DD, Karp JE, Chen TT, Doyle LA.  Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2000 Jul 1;96(1):365-8. PMID: 10891476 [PubMed - indexed for MEDLINE]

Ross DD.  Novel mechanisms of drug resistance in leukemia. Leukemia. 2000 Mar;14(3):467-73. Review. PMID: 10720143 [PubMed - indexed for MEDLINE]

Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000 Jan 1;60(1):47-50. PMID: 10646850 [PubMed - indexed for MEDLINE]

Ross DD, Keay T, Timmel D, Alexander C, Dignon C, O'Mara A, O'Brien W 3rd.  Required training in hospice and palliative care at the University of Maryland School of Medicine. J Cancer Educ. 1999 Fall;14(3):132-6. PMID: 10512327 [PubMed - indexed for MEDLINE]

Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA.  Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.J Natl Cancer Inst. 1999 Mar 3;91(5):429-33. PMID: 10070941 [PubMed - indexed for MEDLINE]

Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD.  A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70. PMID: 9861027 [PubMed - indexed for MEDLINE]